Skip to content

Study · Randomized controlled trial · n = 59 · 2012

13 results

Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.

Yuan GH, Song WL, Huang YY, Guo XH, Gao Y

Chinese medical journal1 Aug 2012Cited by 20 (Europe PMC)

PMID22931974 (opens in a new tab)PepBankPUB-22931974
Publisher pageAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In obese patients with newly diagnosed diabetes, exenatide reduced HbA1c more than metformin.

    In plain wordsIn obese patients with newly diagnosed diabetes, exenatide reduced HbA1c more than metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c reduction
    Study

    n = 59

    Comparator
    metformin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −2.1%
    exenatide
    HbA1c change
    −1.66%
    metformin

    Source sentences

    Summary
    HbA(1C) and oral glucose tolerance test (OGTT) 2 hour glycemia reduction with exenatide was superior to that obtained with metformin ((-2.10 ± 1.79)% vs. (-1.66 ± 1.38)%, (-5.11 ± 2.68) mmol/L vs. (-2.80 ± 2.70) mmol/L, P < 0.05).
    2 context sentences
    Summary · context
    A 26-week, metformin controlled, parallel-group study was conducted among antidiabetic drug-naive obese patients aged > 18 years, and with type 2 diabetes.
    Summary · context
    Participating patients were randomly assigned to receive exenatide or metformin treatments.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In obese patients with newly diagnosed diabetes, exenatide reduced OGTT two-hour glycemia more than metformin.

    In plain wordsIn obese patients with newly diagnosed diabetes, exenatide reduced blood sugar after glucose testing more than metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseOGTT 2-hour glycemia reduction
    Study

    n = 59

    Comparator
    metformin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    OGTT glycemia change
    −5.11 mmol/L
    exenatide
    OGTT glycemia change
    −2.8 mmol/L
    metformin

    Source sentences

    Summary
    HbA(1C) and oral glucose tolerance test (OGTT) 2 hour glycemia reduction with exenatide was superior to that obtained with metformin ((-2.10 ± 1.79)% vs. (-1.66 ± 1.38)%, (-5.11 ± 2.68) mmol/L vs. (-2.80 ± 2.70) mmol/L, P < 0.05).
    2 context sentences
    Summary · context
    A 26-week, metformin controlled, parallel-group study was conducted among antidiabetic drug-naive obese patients aged > 18 years, and with type 2 diabetes.
    Summary · context
    Participating patients were randomly assigned to receive exenatide or metformin treatments.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In obese patients with newly diagnosed diabetes, fasting glucose reduction did not differ significantly between exenatide and metformin.

    In plain wordsIn obese patients with newly diagnosed diabetes, fasting blood sugar reductions did not differ significantly between exenatide and metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeFasting plasma glucose reduction
    Study

    n = 59

    Comparator
    metformin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    FPG change
    −1.8 mmol/L
    exenatide
    FPG change
    −1.6 mmol/L
    metformin

    Source sentences

    Summary
    Fast plasma glucose (FPG) reduction was not significantly different between the two groups ((-1.8 ± 2.0) mmol/L vs. (-1.6 ± 1.7) mmol/L, P > 0.05).
    2 context sentences
    Summary · context
    A 26-week, metformin controlled, parallel-group study was conducted among antidiabetic drug-naive obese patients aged > 18 years, and with type 2 diabetes.
    Summary · context
    Participating patients were randomly assigned to receive exenatide or metformin treatments.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In obese patients with newly diagnosed diabetes, HbA1c below 7% occurred in 97% with exenatide versus 93% with metformin, without significant difference.

    In plain wordsIn obese patients with diabetes, HbA1c below 7% occurred in 97% with exenatide versus 93% with metformin, without significant difference.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeHbA1c below 7%
    Study

    n = 59

    Comparator
    metformin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    Responders
    97%
    exenatide
    Responders
    93%
    metformin

    Source sentences

    Summary
    Patients treated with exenatide achieved HbA(1C) of 0.05).
    2 context sentences
    Summary · context
    A 26-week, metformin controlled, parallel-group study was conducted among antidiabetic drug-naive obese patients aged > 18 years, and with type 2 diabetes.
    Summary · context
    Participating patients were randomly assigned to receive exenatide or metformin treatments.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In obese patients with newly diagnosed diabetes, HbA1c below 6.5% occurred in 79% with exenatide versus 73% with metformin, without significant difference.

    In plain wordsIn obese patients with diabetes, HbA1c below 6.5% occurred in 79% with exenatide versus 73% with metformin, without significant difference.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeHbA1c below 6.5%
    Study

    n = 59

    Comparator
    metformin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    Responders
    79%
    exenatide
    Responders
    73%
    metformin

    Source sentences

    Summary
    Patients treated with exenatide achieved HbA(1C) of 0.05).
    2 context sentences
    Summary · context
    A 26-week, metformin controlled, parallel-group study was conducted among antidiabetic drug-naive obese patients aged > 18 years, and with type 2 diabetes.
    Summary · context
    Participating patients were randomly assigned to receive exenatide or metformin treatments.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In obese patients with newly diagnosed diabetes, exenatide reduced weight more than metformin.

    In plain wordsIn obese patients with newly diagnosed diabetes, exenatide reduced weight more than metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight reduction
    Study

    n = 59

    Comparator
    metformin
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    Weight change
    −5.8 kg
    exenatide
    Weight change
    −3.81 kg
    metformin

    Source sentences

    Summary
    Greater weight reduction was also achieved with exenatide ((-5.80 ± 3.66) kg) than with metformin ((-3.81 ± 1.38) kg, P < 0.01).
    2 context sentences
    Summary · context
    A 26-week, metformin controlled, parallel-group study was conducted among antidiabetic drug-naive obese patients aged > 18 years, and with type 2 diabetes.
    Summary · context
    Participating patients were randomly assigned to receive exenatide or metformin treatments.
  7. 07HumanRandomized controlled trialSafety outcome

    In obese patients with newly diagnosed diabetes, nausea was more frequent with exenatide than metformin, mostly mild to moderate.

    In plain wordsIn obese patients with diabetes, nausea was more frequent with exenatide than metformin, mostly mild to moderate.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseNausea
    Study

    n = 59

    Comparator
    metformin
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    Nausea
    30%
    exenatide
    Nausea
    8%
    metformin

    Source sentences

    Summary
    Nausea was the most common adverse effect in exenatide treatment (30% vs. 8%; P < 0.05), but most cases were of mild to moderate intensity.
    2 context sentences
    Summary · context
    A 26-week, metformin controlled, parallel-group study was conducted among antidiabetic drug-naive obese patients aged > 18 years, and with type 2 diabetes.
    Summary · context
    Participating patients were randomly assigned to receive exenatide or metformin treatments.
  8. 08HumanRandomized controlled trialSafety outcome

    In obese patients with newly diagnosed diabetes, hypoglycemia was more frequent with exenatide than metformin, often during the first 4 weeks.

    In plain wordsIn obese patients with diabetes, low blood sugar was more frequent with exenatide than metformin, often during the first 4 weeks.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseHypoglycemia
    Study

    n = 59

    Comparator
    metformin
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    Hypoglycemia
    12%
    exenatide
    Hypoglycemia
    3.2%
    metformin

    Source sentences

    Summary
    Hypoglycemia events were often observed during the first 4 weeks, with 12% of patients in the exenatide and 3.2% in metformin groups, respectively (P < 0.05).
    2 context sentences
    Summary · context
    A 26-week, metformin controlled, parallel-group study was conducted among antidiabetic drug-naive obese patients aged > 18 years, and with type 2 diabetes.
    Summary · context
    Participating patients were randomly assigned to receive exenatide or metformin treatments.
  9. 09HumanRandomized controlled trialSafety outcome

    In obese patients with newly diagnosed diabetes, no severe hypoglycemia incidents were reported.

    In plain wordsIn obese patients with newly diagnosed diabetes, no severe low-blood-sugar events were reported.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableSevere hypoglycemia
    Study

    n = 59

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    No incidents of severe hypoglycemia were reported.
    3 context sentences
    Summary · context
    A 26-week, metformin controlled, parallel-group study was conducted among antidiabetic drug-naive obese patients aged > 18 years, and with type 2 diabetes.
    Summary · context
    Participating patients were randomly assigned to receive exenatide or metformin treatments.
    Summary · context
    Fifty-nine patients (age (50.5 ± 8.6) years, body mass index (BMI) (30.2 ± 1.6) kg/m(2), and hemoglobin A1C (HbA(1C) (8.2 ± 1.2)%) were enrolled in the study.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In obese patients with newly diagnosed diabetes, HOMA-B did not increase significantly during exenatide treatment.

    In plain wordsIn obese patients with newly diagnosed diabetes, the HOMA-B measure did not increase significantly during exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeHOMA-B
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Homeostasis model assessment of beta-cell function (HOMA-B) was not significantly increased, but the insulinogenic index and HOMA for insulin sensitivity (HOMA-S) were greatly improved in the exenatide group (P < 0.05).
    2 context sentences
    Summary · context
    A 26-week, metformin controlled, parallel-group study was conducted among antidiabetic drug-naive obese patients aged > 18 years, and with type 2 diabetes.
    Summary · context
    Participating patients were randomly assigned to receive exenatide or metformin treatments.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In obese patients with newly diagnosed diabetes, insulinogenic index improved during exenatide treatment.

    In plain wordsIn obese patients with newly diagnosed diabetes, the insulin secretion index improved during exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseInsulinogenic index
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Homeostasis model assessment of beta-cell function (HOMA-B) was not significantly increased, but the insulinogenic index and HOMA for insulin sensitivity (HOMA-S) were greatly improved in the exenatide group (P < 0.05).
    2 context sentences
    Summary · context
    A 26-week, metformin controlled, parallel-group study was conducted among antidiabetic drug-naive obese patients aged > 18 years, and with type 2 diabetes.
    Summary · context
    Participating patients were randomly assigned to receive exenatide or metformin treatments.
  12. 12HumanRandomized controlled trialEfficacy outcome

    In obese patients with newly diagnosed diabetes, HOMA-S improved during exenatide treatment.

    In plain wordsIn obese patients with newly diagnosed diabetes, the insulin sensitivity measure improved during exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseHOMA-S
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Homeostasis model assessment of beta-cell function (HOMA-B) was not significantly increased, but the insulinogenic index and HOMA for insulin sensitivity (HOMA-S) were greatly improved in the exenatide group (P < 0.05).
    2 context sentences
    Summary · context
    A 26-week, metformin controlled, parallel-group study was conducted among antidiabetic drug-naive obese patients aged > 18 years, and with type 2 diabetes.
    Summary · context
    Participating patients were randomly assigned to receive exenatide or metformin treatments.
  13. 13HumanRandomized controlled trialSafety outcome

    In obese patients with newly diagnosed diabetes, one exenatide recipient withdrew early because of severe nausea.

    In plain wordsIn obese patients with newly diagnosed diabetes, one exenatide recipient stopped treatment early because of severe nausea.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableWithdrawal due to severe nausea
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    Withdrawal
    1 patient
    severe nausea with exenatide

    Source sentences

    Summary
    One case in the exenatide group was withdrawn early because of severe nausea.
    2 context sentences
    Summary · context
    A 26-week, metformin controlled, parallel-group study was conducted among antidiabetic drug-naive obese patients aged > 18 years, and with type 2 diabetes.
    Summary · context
    Participating patients were randomly assigned to receive exenatide or metformin treatments.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.